Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

Figure 5

The treatment effects of 10 mg everolimus (E 10 ) for patients from the everolimus arm ( n = 272) who had at least 1 dose reduction to 5 mg and/or 0 mg ( n = 174) versus no dose reduction ( n = 98). The line within the grey box indicates the median value, the grey box indicates the upper and lower quartile, and the grey lines above and below the box indicate the 5th and 95th percentiles.

Back to article page